stoxline Quote Chart Rank Option Currency Glossary
  
SOPHiA GENETICS SA (SOPH)
4.95  -0.06 (-1.2%)    04-23 10:51
Open: 4.99
High: 5
Volume: 12,456
  
Pre. Close: 5.01
Low: 4.8503
Market Cap: 323(M)
Technical analysis
2024-04-23 10:51:11 AM
Short term     
Mid term     
Targets 6-month :  6.23 1-year :  7.28
Resists First :  5.34 Second :  6.23
Pivot price 4.95
Supports First :  4.7 Second :  4.3
MAs MA(5) :  4.9 MA(20) :  4.96
MA(100) :  4.74 MA(250) :  4.07
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  50 D(3) :  41.4
RSI RSI(14): 50.5
52-week High :  7.36 Low :  2.13
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SOPH ] has closed above bottom band by 42.1%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.25 - 5.28 5.28 - 5.3
Low: 4.81 - 4.83 4.83 - 4.85
Close: 4.97 - 5 5 - 5.04
Company Description

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Headline News

Tue, 23 Apr 2024
2024-04-23 | NDAQ:SOPH | Press Release | SOPHiA GENETICS SA - Stockhouse Publishing

Thu, 04 Apr 2024
SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership - Marketscreener.com

Sat, 09 Mar 2024
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Released Its Yearly Results And Analysts Are Updating Their Estimates - Yahoo Finance

Sat, 09 Mar 2024
SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Simply Wall St

Wed, 06 Mar 2024
SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2023 Earnings Call Transcript - Yahoo Finance

Tue, 05 Mar 2024
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Se - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Healthcare Information Services
Shares Out 65 (M)
Shares Float 46 (M)
Held by Insiders 5.9 (%)
Held by Institutions 50 (%)
Shares Short 53 (K)
Shares Short P.Month 60 (K)
Stock Financials
EPS -1.23
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.31
Profit Margin -126.7 %
Operating Margin -111 %
Return on Assets (ttm) -20.8 %
Return on Equity (ttm) -45 %
Qtrly Rev. Growth 27.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.95
EBITDA (p.s.) -1.12
Qtrly Earnings Growth 0 %
Operating Cash Flow -49 (M)
Levered Free Cash Flow -31 (M)
Stock Valuations
PE Ratio -4.05
PEG Ratio 0
Price to Book value 2.12
Price to Sales 5.16
Price to Cash Flow -6.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android